nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—Monoparesis—Hydrochlorothiazide—nephrolithiasis	0.0865	0.126	CcSEcCtD
Tacrolimus—PPP3CA—nephron—nephrolithiasis	0.0766	0.254	CbGeAlD
Tacrolimus—ABCA5—nephron tubule—nephrolithiasis	0.0245	0.0813	CbGeAlD
Tacrolimus—Sensation of warmth—Hydrochlorothiazide—nephrolithiasis	0.0231	0.0338	CcSEcCtD
Tacrolimus—ABCA5—cortex of kidney—nephrolithiasis	0.0209	0.0696	CbGeAlD
Tacrolimus—PPP3CA—nephron tubule—nephrolithiasis	0.0165	0.0549	CbGeAlD
Tacrolimus—Arrhythmia supraventricular—Hydrochlorothiazide—nephrolithiasis	0.0161	0.0235	CcSEcCtD
Tacrolimus—PPP3CA—renal system—nephrolithiasis	0.015	0.0499	CbGeAlD
Tacrolimus—PPP3CA—kidney—nephrolithiasis	0.0145	0.0483	CbGeAlD
Tacrolimus—PPP3CA—cortex of kidney—nephrolithiasis	0.0142	0.047	CbGeAlD
Tacrolimus—CYP3A4—urine—nephrolithiasis	0.0133	0.0443	CbGeAlD
Tacrolimus—Anorectal disorder—Hydrochlorothiazide—nephrolithiasis	0.0118	0.0173	CcSEcCtD
Tacrolimus—CYP3A7-CYP3A51P—nephron tubule—nephrolithiasis	0.0116	0.0384	CbGeAlD
Tacrolimus—MTOR—renal system—nephrolithiasis	0.0111	0.0369	CbGeAlD
Tacrolimus—MTOR—kidney—nephrolithiasis	0.0107	0.0357	CbGeAlD
Tacrolimus—FKBP1A—renal system—nephrolithiasis	0.00998	0.0332	CbGeAlD
Tacrolimus—CYP3A7-CYP3A51P—cortex of kidney—nephrolithiasis	0.00989	0.0329	CbGeAlD
Tacrolimus—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.0098	0.0143	CcSEcCtD
Tacrolimus—Encephalopathy—Hydrochlorothiazide—nephrolithiasis	0.0097	0.0142	CcSEcCtD
Tacrolimus—FKBP1A—kidney—nephrolithiasis	0.00965	0.0321	CbGeAlD
Tacrolimus—FKBP1A—cortex of kidney—nephrolithiasis	0.0094	0.0312	CbGeAlD
Tacrolimus—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.00864	0.0126	CcSEcCtD
Tacrolimus—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00841	0.0123	CcSEcCtD
Tacrolimus—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00813	0.0119	CcSEcCtD
Tacrolimus—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.00794	0.0116	CcSEcCtD
Tacrolimus—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.00769	0.0112	CcSEcCtD
Tacrolimus—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00757	0.0111	CcSEcCtD
Tacrolimus—Jaundice cholestatic—Hydrochlorothiazide—nephrolithiasis	0.00709	0.0104	CcSEcCtD
Tacrolimus—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.00704	0.0103	CcSEcCtD
Tacrolimus—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.0069	0.0101	CcSEcCtD
Tacrolimus—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.00671	0.00981	CcSEcCtD
Tacrolimus—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00671	0.00981	CcSEcCtD
Tacrolimus—Gout—Hydrochlorothiazide—nephrolithiasis	0.00667	0.00975	CcSEcCtD
Tacrolimus—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00658	0.00962	CcSEcCtD
Tacrolimus—Coordination abnormal—Hydrochlorothiazide—nephrolithiasis	0.00634	0.00927	CcSEcCtD
Tacrolimus—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00634	0.00927	CcSEcCtD
Tacrolimus—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00612	0.00894	CcSEcCtD
Tacrolimus—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.00588	0.00859	CcSEcCtD
Tacrolimus—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00569	0.00831	CcSEcCtD
Tacrolimus—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00563	0.00823	CcSEcCtD
Tacrolimus—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.00554	0.0081	CcSEcCtD
Tacrolimus—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.0052	0.00759	CcSEcCtD
Tacrolimus—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.00515	0.00752	CcSEcCtD
Tacrolimus—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.0051	0.00745	CcSEcCtD
Tacrolimus—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00501	0.00732	CcSEcCtD
Tacrolimus—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00496	0.00725	CcSEcCtD
Tacrolimus—Injury—Hydrochlorothiazide—nephrolithiasis	0.00492	0.00719	CcSEcCtD
Tacrolimus—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00483	0.00706	CcSEcCtD
Tacrolimus—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00481	0.00703	CcSEcCtD
Tacrolimus—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00479	0.007	CcSEcCtD
Tacrolimus—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00479	0.007	CcSEcCtD
Tacrolimus—CYP3A5—nephron tubule—nephrolithiasis	0.00478	0.0159	CbGeAlD
Tacrolimus—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00477	0.00697	CcSEcCtD
Tacrolimus—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00475	0.00694	CcSEcCtD
Tacrolimus—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00475	0.00694	CcSEcCtD
Tacrolimus—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00465	0.0068	CcSEcCtD
Tacrolimus—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00454	0.00663	CcSEcCtD
Tacrolimus—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00452	0.00661	CcSEcCtD
Tacrolimus—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00452	0.00661	CcSEcCtD
Tacrolimus—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00445	0.0065	CcSEcCtD
Tacrolimus—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00445	0.0065	CcSEcCtD
Tacrolimus—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00436	0.00638	CcSEcCtD
Tacrolimus—CYP3A5—renal system—nephrolithiasis	0.00435	0.0144	CbGeAlD
Tacrolimus—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00428	0.00626	CcSEcCtD
Tacrolimus—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00424	0.00619	CcSEcCtD
Tacrolimus—CYP3A5—kidney—nephrolithiasis	0.0042	0.014	CbGeAlD
Tacrolimus—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00417	0.0061	CcSEcCtD
Tacrolimus—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00414	0.00605	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00413	0.00603	CcSEcCtD
Tacrolimus—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00411	0.00601	CcSEcCtD
Tacrolimus—CYP3A5—cortex of kidney—nephrolithiasis	0.00409	0.0136	CbGeAlD
Tacrolimus—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00409	0.00597	CcSEcCtD
Tacrolimus—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00407	0.00595	CcSEcCtD
Tacrolimus—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00407	0.00595	CcSEcCtD
Tacrolimus—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.004	0.00585	CcSEcCtD
Tacrolimus—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00399	0.00583	CcSEcCtD
Tacrolimus—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00393	0.00575	CcSEcCtD
Tacrolimus—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00391	0.00571	CcSEcCtD
Tacrolimus—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00391	0.00571	CcSEcCtD
Tacrolimus—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00383	0.0056	CcSEcCtD
Tacrolimus—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00381	0.00556	CcSEcCtD
Tacrolimus—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00365	0.00534	CcSEcCtD
Tacrolimus—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00365	0.00534	CcSEcCtD
Tacrolimus—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00361	0.00527	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00357	0.00521	CcSEcCtD
Tacrolimus—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00356	0.0052	CcSEcCtD
Tacrolimus—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00352	0.00515	CcSEcCtD
Tacrolimus—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.0035	0.00512	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00345	0.00505	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00343	0.00502	CcSEcCtD
Tacrolimus—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00342	0.005	CcSEcCtD
Tacrolimus—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00342	0.00499	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00342	0.00499	CcSEcCtD
Tacrolimus—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.0034	0.00496	CcSEcCtD
Tacrolimus—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00339	0.00495	CcSEcCtD
Tacrolimus—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00339	0.00495	CcSEcCtD
Tacrolimus—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00334	0.00488	CcSEcCtD
Tacrolimus—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00332	0.00485	CcSEcCtD
Tacrolimus—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00329	0.0048	CcSEcCtD
Tacrolimus—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00478	CcSEcCtD
Tacrolimus—CYP3A4—renal system—nephrolithiasis	0.00326	0.0108	CbGeAlD
Tacrolimus—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00475	CcSEcCtD
Tacrolimus—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00318	0.00465	CcSEcCtD
Tacrolimus—CYP3A4—kidney—nephrolithiasis	0.00315	0.0105	CbGeAlD
Tacrolimus—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00314	0.00458	CcSEcCtD
Tacrolimus—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00313	0.00457	CcSEcCtD
Tacrolimus—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00311	0.00455	CcSEcCtD
Tacrolimus—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.0031	0.00454	CcSEcCtD
Tacrolimus—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00308	0.0045	CcSEcCtD
Tacrolimus—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00301	0.0044	CcSEcCtD
Tacrolimus—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00296	0.00432	CcSEcCtD
Tacrolimus—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00292	0.00426	CcSEcCtD
Tacrolimus—Flushing—Hydrochlorothiazide—nephrolithiasis	0.0029	0.00424	CcSEcCtD
Tacrolimus—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00279	0.00408	CcSEcCtD
Tacrolimus—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00276	0.00404	CcSEcCtD
Tacrolimus—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00272	0.00398	CcSEcCtD
Tacrolimus—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00268	0.00392	CcSEcCtD
Tacrolimus—Tension—Hydrochlorothiazide—nephrolithiasis	0.00267	0.0039	CcSEcCtD
Tacrolimus—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00267	0.0039	CcSEcCtD
Tacrolimus—ALB—Scavenging of heme from plasma—AMBP—nephrolithiasis	0.00265	0.182	CbGpPWpGaD
Tacrolimus—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00386	CcSEcCtD
Tacrolimus—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00263	0.00385	CcSEcCtD
Tacrolimus—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00262	0.00382	CcSEcCtD
Tacrolimus—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00257	0.00375	CcSEcCtD
Tacrolimus—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00373	CcSEcCtD
Tacrolimus—ABCB1—nephron tubule—nephrolithiasis	0.00254	0.00844	CbGeAlD
Tacrolimus—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00369	CcSEcCtD
Tacrolimus—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00252	0.00368	CcSEcCtD
Tacrolimus—Agitation—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00366	CcSEcCtD
Tacrolimus—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00246	0.00359	CcSEcCtD
Tacrolimus—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00245	0.00357	CcSEcCtD
Tacrolimus—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00357	CcSEcCtD
Tacrolimus—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00356	CcSEcCtD
Tacrolimus—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00241	0.00352	CcSEcCtD
Tacrolimus—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00239	0.0035	CcSEcCtD
Tacrolimus—Cough—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00347	CcSEcCtD
Tacrolimus—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00339	CcSEcCtD
Tacrolimus—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00339	CcSEcCtD
Tacrolimus—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00339	CcSEcCtD
Tacrolimus—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00231	0.00337	CcSEcCtD
Tacrolimus—ABCB1—renal system—nephrolithiasis	0.00231	0.00767	CbGeAlD
Tacrolimus—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00335	CcSEcCtD
Tacrolimus—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00227	0.00331	CcSEcCtD
Tacrolimus—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00224	0.00327	CcSEcCtD
Tacrolimus—ABCB1—kidney—nephrolithiasis	0.00223	0.00742	CbGeAlD
Tacrolimus—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00222	0.00325	CcSEcCtD
Tacrolimus—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00222	0.00325	CcSEcCtD
Tacrolimus—Shock—Hydrochlorothiazide—nephrolithiasis	0.00219	0.00319	CcSEcCtD
Tacrolimus—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00218	0.00318	CcSEcCtD
Tacrolimus—ABCB1—cortex of kidney—nephrolithiasis	0.00217	0.00723	CbGeAlD
Tacrolimus—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00217	0.00317	CcSEcCtD
Tacrolimus—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00215	0.00314	CcSEcCtD
Tacrolimus—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00212	0.00309	CcSEcCtD
Tacrolimus—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00208	0.00303	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00202	0.00296	CcSEcCtD
Tacrolimus—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00201	0.00294	CcSEcCtD
Tacrolimus—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.002	0.00292	CcSEcCtD
Tacrolimus—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00198	0.00289	CcSEcCtD
Tacrolimus—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00198	0.00289	CcSEcCtD
Tacrolimus—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00196	0.00286	CcSEcCtD
Tacrolimus—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00193	0.00282	CcSEcCtD
Tacrolimus—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00192	0.0028	CcSEcCtD
Tacrolimus—Constipation—Hydrochlorothiazide—nephrolithiasis	0.0019	0.00278	CcSEcCtD
Tacrolimus—Pain—Hydrochlorothiazide—nephrolithiasis	0.0019	0.00278	CcSEcCtD
Tacrolimus—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00268	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00182	0.00265	CcSEcCtD
Tacrolimus—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00177	0.00258	CcSEcCtD
Tacrolimus—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00176	0.00257	CcSEcCtD
Tacrolimus—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00176	0.00257	CcSEcCtD
Tacrolimus—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00164	0.00239	CcSEcCtD
Tacrolimus—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00159	0.00233	CcSEcCtD
Tacrolimus—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00157	0.0023	CcSEcCtD
Tacrolimus—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00152	0.00222	CcSEcCtD
Tacrolimus—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00147	0.00215	CcSEcCtD
Tacrolimus—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00141	0.00206	CcSEcCtD
Tacrolimus—Rash—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00205	CcSEcCtD
Tacrolimus—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00204	CcSEcCtD
Tacrolimus—Headache—Hydrochlorothiazide—nephrolithiasis	0.00139	0.00203	CcSEcCtD
Tacrolimus—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00132	0.00193	CcSEcCtD
Tacrolimus—ALB—Binding and Uptake of Ligands by Scavenger Receptors—AMBP—nephrolithiasis	0.00106	0.0727	CbGpPWpGaD
Tacrolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.000877	0.0604	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—AQP1—nephrolithiasis	0.000736	0.0507	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—AQP1—nephrolithiasis	0.000571	0.0393	CbGpPWpGaD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—SPP1—nephrolithiasis	0.000443	0.0305	CbGpPWpGaD
Tacrolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.000428	0.0295	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—ATP6V0A4—nephrolithiasis	0.000407	0.028	CbGpPWpGaD
Tacrolimus—CYP3A7—Biological oxidations—SLC26A1—nephrolithiasis	0.000263	0.0181	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—RGS14—nephrolithiasis	0.000244	0.0168	CbGpPWpGaD
Tacrolimus—CYP3A5—Biological oxidations—SLC26A1—nephrolithiasis	0.00019	0.0131	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000183	0.0126	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ADCY10—nephrolithiasis	0.00017	0.0117	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000167	0.0115	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000167	0.0115	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—DGKH—nephrolithiasis	0.000165	0.0113	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—SLC26A1—nephrolithiasis	0.000156	0.0107	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RGS14—nephrolithiasis	0.000144	0.00992	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—ATP6V0A4—nephrolithiasis	0.000139	0.00957	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ADCY10—nephrolithiasis	0.000131	0.00905	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000127	0.00871	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000127	0.00871	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SLC26A1—nephrolithiasis	0.000121	0.00833	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000119	0.00822	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CHRM3—nephrolithiasis	0.000119	0.0082	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000118	0.0081	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000118	0.0081	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—SPP1—nephrolithiasis	0.000114	0.00782	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RGS14—nephrolithiasis	0.000112	0.00769	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—PTH—nephrolithiasis	0.000109	0.0075	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—ATP6V0A4—nephrolithiasis	0.000108	0.00742	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000105	0.00722	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000104	0.00716	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000104	0.00716	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ATP6V0A4—nephrolithiasis	9.74e-05	0.0067	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—DGKH—nephrolithiasis	9.74e-05	0.0067	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—SPP1—nephrolithiasis	9.42e-05	0.00649	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	9.28e-05	0.00639	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	9.12e-05	0.00628	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	9.12e-05	0.00628	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	8.84e-05	0.00608	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	8.48e-05	0.00584	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	8.48e-05	0.00584	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	8.13e-05	0.00559	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	7.55e-05	0.0052	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—DGKH—nephrolithiasis	7.55e-05	0.0052	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	7.43e-05	0.00512	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	7.43e-05	0.00512	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ADCY10—nephrolithiasis	7.39e-05	0.00509	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CHRM3—nephrolithiasis	7.04e-05	0.00485	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SLC26A1—nephrolithiasis	6.8e-05	0.00468	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTH—nephrolithiasis	6.44e-05	0.00443	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	6.43e-05	0.00443	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	6.43e-05	0.00443	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RGS14—nephrolithiasis	6.29e-05	0.00433	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SLC7A9—nephrolithiasis	6.15e-05	0.00424	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—DGKH—nephrolithiasis	6.15e-05	0.00424	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ATP6V0A4—nephrolithiasis	6.06e-05	0.00417	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	5.98e-05	0.00411	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	5.98e-05	0.00411	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GRHPR—nephrolithiasis	5.93e-05	0.00408	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	5.63e-05	0.00388	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	5.63e-05	0.00388	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CHRM3—nephrolithiasis	5.46e-05	0.00376	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	5.33e-05	0.00367	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	5.33e-05	0.00367	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AGXT—nephrolithiasis	5.29e-05	0.00364	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	5.24e-05	0.00361	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	5.24e-05	0.00361	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTH—nephrolithiasis	4.99e-05	0.00344	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	4.67e-05	0.00321	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	4.67e-05	0.00321	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—SLC26A1—nephrolithiasis	4.5e-05	0.0031	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APRT—nephrolithiasis	4.5e-05	0.0031	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GRHPR—nephrolithiasis	4.29e-05	0.00295	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—AQP1—nephrolithiasis	4.26e-05	0.00293	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.25e-05	0.00292	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—DGKH—nephrolithiasis	4.25e-05	0.00292	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AGXT—nephrolithiasis	3.82e-05	0.00263	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	3.73e-05	0.00257	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GRHPR—nephrolithiasis	3.69e-05	0.00254	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AGXT—nephrolithiasis	3.29e-05	0.00227	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APRT—nephrolithiasis	3.25e-05	0.00224	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SLC26A1—nephrolithiasis	3.25e-05	0.00224	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GRHPR—nephrolithiasis	3.24e-05	0.00223	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SPP1—nephrolithiasis	3.23e-05	0.00223	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AQP1—nephrolithiasis	3.2e-05	0.00221	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CHRM3—nephrolithiasis	3.07e-05	0.00211	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CHRM3—nephrolithiasis	2.9e-05	0.00199	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AGXT—nephrolithiasis	2.88e-05	0.00199	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTH—nephrolithiasis	2.81e-05	0.00193	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SLC26A1—nephrolithiasis	2.8e-05	0.00193	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APRT—nephrolithiasis	2.8e-05	0.00193	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SPP1—nephrolithiasis	2.51e-05	0.00173	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APRT—nephrolithiasis	2.45e-05	0.00169	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC26A1—nephrolithiasis	2.45e-05	0.00169	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AQP1—nephrolithiasis	2.32e-05	0.00159	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CHRM3—nephrolithiasis	2.09e-05	0.00144	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AQP1—nephrolithiasis	1.99e-05	0.00137	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GRHPR—nephrolithiasis	1.99e-05	0.00137	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CHRM3—nephrolithiasis	1.8e-05	0.00124	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AGXT—nephrolithiasis	1.78e-05	0.00122	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AQP1—nephrolithiasis	1.75e-05	0.0012	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CHRM3—nephrolithiasis	1.58e-05	0.00109	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APRT—nephrolithiasis	1.51e-05	0.00104	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	1.51e-05	0.00104	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SPP1—nephrolithiasis	1.41e-05	0.00097	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AQP1—nephrolithiasis	1.08e-05	0.000741	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CHRM3—nephrolithiasis	9.74e-06	0.00067	CbGpPWpGaD
